259 related articles for article (PubMed ID: 32041464)
1. Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?
Oduah EI; Grossman SR
Cancer Biol Ther; 2020 Apr; 21(4):293-302. PubMed ID: 32041464
[TBL] [Abstract][Full Text] [Related]
2. Plakoglobin restores tumor suppressor activity of p53
Alaee M; Nool K; Pasdar M
Cancer Sci; 2018 Jun; 109(6):1876-1888. PubMed ID: 29660231
[TBL] [Abstract][Full Text] [Related]
3. The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3.
Vaughan CA; Singh S; Subler MA; Windle JJ; Inoue K; Fry EA; Pillappa R; Grossman SR; Windle B; Andrew Yeudall W; Deb SP; Deb S
Nat Commun; 2021 Jan; 12(1):704. PubMed ID: 33514736
[TBL] [Abstract][Full Text] [Related]
4. Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter.
Vaughan CA; Pearsall I; Singh S; Windle B; Deb SP; Grossman SR; Yeudall WA; Deb S
Oncotarget; 2016 Mar; 7(11):12426-46. PubMed ID: 26820293
[TBL] [Abstract][Full Text] [Related]
5. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
[TBL] [Abstract][Full Text] [Related]
7. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
Barta JA; Pauley K; Kossenkov AV; McMahon SB
Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
[TBL] [Abstract][Full Text] [Related]
8. Lung-Enriched Mutations in the p53 Tumor Suppressor: A Paradigm for Tissue-Specific Gain of Oncogenic Function.
Barta JA; McMahon SB
Mol Cancer Res; 2019 Jan; 17(1):3-9. PubMed ID: 30224539
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?
Choudhury S; Kolukula VK; Preet A; Albanese C; Avantaggiati ML
Cell Cycle; 2013 Apr; 12(7):1022-9. PubMed ID: 23466706
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-324-5p-CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness.
Ghatak D; Datta A; Roychowdhury T; Chattopadhyay S; Roychoudhury S
Mol Cancer Res; 2021 Oct; 19(10):1635-1650. PubMed ID: 34257080
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
12. Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.
Frum RA; Love IM; Damle PK; Mukhopadhyay ND; Palit Deb S; Deb S; Grossman SR
Mol Cancer Res; 2016 May; 14(5):423-36. PubMed ID: 26965143
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication.
Singh S; Vaughan CA; Frum RA; Grossman SR; Deb S; Palit Deb S
J Clin Invest; 2017 May; 127(5):1839-1855. PubMed ID: 28394262
[TBL] [Abstract][Full Text] [Related]
14. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
15. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
17. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
[TBL] [Abstract][Full Text] [Related]
19. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
20. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
